BigThink Reports 235% Surge in First-Half Revenue, Expects to Surpass 10 Billion Won This Year

BigThink Therapeutics (BigThink), a subsidiary of Kipsbiopharma (Kipspharma), saw its revenue in the first half of this year increase more than threefold compared to the same period last year, putting the company on track to surpass annual revenue of 10 billion won. With sales growth of its key anticancer drugs combined with the successful market entry of newly introduced products, industry observers note that BigThink’s growth as a cancer-focused pharmaceutical company is accelerating.

On September 4, BigThink announced that its cumulative sales reached 5.6 billion won by the end of the second quarter this year. This figure surpassed last year’s annual revenue of 5.1 billion won in just the first half, representing a 235% increase over the same period last year.

The company’s recent financial performance has shown steady growth. BigThink’s annual sales grew from 3.5 billion won in 2024 to 5.1 billion won in 2025. This year, its first-half revenue alone outpaced last year's total, and the company also turned a profit in terms of operating income.

The primary drivers of this performance were the expanding sales of existing main products and the full-scale launch of new anticancer drugs. 'Nurynx', the flagship breast cancer treatment, saw its sales in the first half jump 58% year-on-year. Industry sources attribute this achievement to specialized sales and marketing strategies for major general hospitals and oncology specialists, leveraging the company’s expertise in the anticancer sector.

The five anticancer products, for which BigThink has an exclusive distribution agreement with Handok Teva, are rapidly expanding their sales base. These products accounted for 18% of BigThink’s total sales in the first half of this year, establishing themselves as major revenue streams.

BigThink has also seen positive results in its overseas business. The company’s oral mucositis treatment for cancer patients, 'Mucosamin', for which it secured Asian rights, expanded exports focusing on Taiwan, Thailand, and Malaysia. As a result, sales of this product increased more than eightfold compared to last year.

The company cited its sales and marketing organization focused on oncology, as well as a strong network of tertiary hospitals and oncology specialists, as the core drivers behind its growth. Furthermore, BigThink explained that it maximized business performance by leveraging synergies among anticancer products like Nurynx and Ronquix, and by adopting product-specific sales strategies.

The company highlighted that sales of new products added to the growth of existing items, and that the effect of an expanded product portfolio has begun to materialize in earnest. BigThink plans to continue enhancing its portfolio by introducing new products and further expanding the scale of its business, all grounded in its expertise in the oncology field.

Man-Kee Kim, Executive Director of BigThink, stated, “The expertise in oncology and sales capabilities we have accumulated are bearing fruit, and we expect to achieve record high results this year, surpassing 10 billion won in sales. By introducing a variety of new products currently being prepared and boosting the competitiveness of our anticancer drug portfolio, we will continue our strong growth trajectory going forward.”

BigThink aims to exceed annual revenue of 10 billion won this year, driven by increased sales of leading anticancer treatments, successful market penetration of new products, and growing overseas exports.

This content was produced with the assistance of AI translation services.